STXS

Stereotaxis, Inc.

NYSE · Electromedical & Electrotherapeutic Apparatus · Inc. DE · CIK 0001289340

$1.81 +1.69% $180.8M

4 New Institutional Positions

Vol

Market Cap$180.8M

Cap SizeMicro Cap

Analyst ConsensusStrong Buy (90%)

Inst. Holders8 funds

Inst. Value$11.0M

Inst. Activity4 buys / 1 sells

SEC Reports7

Press Releases2

Exchange NYSE·Sector Electromedical & Electrotherapeutic Apparatus·Inc. DE·CIK 0001289340·Prev Close $1.78

Recent Activity

May 12, 2026 SEC

Stereotaxis reported Q1 2026 revenue of $6.3M, down 16% YoY from $7.5M, and a GAAP net loss per share of -$0.06, in line

8-K — Impact 6/10

May 12, 2026 SEC

Stereotaxis reported Q1 2026 revenue of $6.3M (down 16% YoY from $7.5M) and EPS of -$0.06, missing the consensus estimat

PRESS-RELEASE — Impact 6/10

Apr 21, 2026 SEC

Stereotaxis announced a future earnings release date for Q1 2026, with no financial results or guidance provided in this

PRESS-RELEASE — Impact 3/10

Apr 11, 2026 Insider

Peery Kimberly R. sold 40,000 shares

Chief Financial Officer @ $0.00 ($0.00)

Inst.

MORGAN STANLEY — ADD

191,848 shares ($441.3K)

Inst.

BANK OF AMERICA CORP — ADD

90,628 shares ($208.4K)

May 12, 2026 earnings

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.

Apr 15, 2026 Press

Stereotaxis (STXS) announced a definitive agreement to acquire Robocath, a French innovator in robotic interventional ca

Impact 7/10

Price Targets

$4.13 +123.0% upside Strong Buy

Current $1.85 Low $3.50 Median $4.00 High $5.00 4 analysts

$3.50 $5.00

Analyst Ratings

Strong Buy90% buy · 10 analysts

2Strong Buy

7Buy

1Hold

0Sell

0Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
May 13, 2026	Piper Sandler	REITERATE	Overweight → Overweight
Dec 16, 2025	Citizens	INITIATE	Market Outperform

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.05 ▲ +11.1%	$-0.06 — $-0.03	7% YoY	3
Next Q	$-0.05 ▼ -16.7%	$-0.06 — $-0.04	33% YoY	3
Current FY	$-0.19 ▼ -2.7%	$-0.23 — $-0.17	24% YoY	3
Next FY	$-0.13 ▼ -3.4%	$-0.18 — $-0.07	33% YoY	3

Latest Reports

BEARISH 8-K 6/10

Stereotaxis reported Q1 2026 revenue of $6.3M, down 16% YoY from $7.5M, and a GAAP net loss per share of -$0.06, in line

May 12, 2026

MIXED PRESS-RELEASE 6/10

Stereotaxis reported Q1 2026 revenue of $6.3M (down 16% YoY from $7.5M) and EPS of -$0.06, missing the consensus estimat

May 12, 2026

BULLISH Press 7/10

Stereotaxis (STXS) announced a definitive agreement to acquire Robocath, a French innovator in robotic interventional ca

Apr 15, 2026

Top Institutional Holders

Fund	Value	Move
VANGUARD GROUP INC	$8.5M	—
RENAISSANCE TECHNOLOGIES LLC	$1.0M	DOUBLED
MORGAN STANLEY	$441.3K	ADD
CHARLES SCHWAB INVESTMENT MANAGEMENT	$437.9K	NEW
BANK OF AMERICA CORP	$208.4K	ADD

Recent Insider Trades

Date	Insider	Type	Value
Apr 11, 2026	Peery Kimberly	A	$0.00

8 institutional holders with $11.0M total value (4,789,345 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 4 institutions added/increased vs 1 reduced.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	VANGUARD GROUP INC	3,692,754	$8.5M	77.1%	—
2	RENAISSANCE TECHNOLOGIES LLC	448,400	$1.0M	9.4%	DOUBLED +768.5%
3	MORGAN STANLEY	191,848	$441.3K	4.0%	ADD +63.0%
4	CHARLES SCHWAB INVESTMENT MANAGEMENT INC	190,387	$437.9K	4.0%	NEW
5	BANK OF AMERICA CORP /DE/	90,628	$208.4K	1.9%	ADD +43.6%
6	TWO SIGMA INVESTMENTS, LP	67,729	$155.8K	1.4%	NEAR_EXIT -81.3%
7	WELLS FARGO & COMPANY/MN	66,452	$152.8K	1.4%	ADD +73.4%
8	FMR LLC	41,147	$94.6K	0.9%	ADD +87.4%

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
MORGAN STANLEY	ADD	117,728	191,848	+63.0%	$441.3K	2025-Q4
BANK OF AMERICA CORP /DE/	ADD	63,114	90,628	+43.6%	$208.4K	2025-Q4
TWO SIGMA INVESTMENTS, LP	NEAR_EXIT	361,888	67,729	-81.3%	$155.8K	2025-Q4
WELLS FARGO & COMPANY/MN	ADD	38,331	66,452	+73.4%	$152.8K	2025-Q4
FMR LLC	ADD	21,953	41,147	+87.4%	$94.6K	2025-Q4
RENAISSANCE TECHNOLOGIES LLC	DOUBLED	43,800	380,400	+768.5%	$1.2M	2025-Q3
TWO SIGMA INVESTMENTS, LP	NEW	—	361,888	—	$1.1M	2025-Q3
MORGAN STANLEY	TRIM	183,022	117,728	-35.7%	$366.1K	2025-Q3
WELLS FARGO & COMPANY/MN	ADD	30,045	38,331	+27.6%	$119.2K	2025-Q3
UBS Group AG	ADD	35,736	70,382	+96.9%	$149.2K	2025-Q2
RENAISSANCE TECHNOLOGIES LLC	TRIM	122,109	43,800	-64.1%	$92.9K	2025-Q2
FMR LLC	DOUBLED	5,212	21,778	+317.8%	$46.2K	2025-Q2
RENAISSANCE TECHNOLOGIES LLC	TRIM	406,200	122,109	-69.9%	$214.9K	2025-Q1
FMR LLC	DOUBLED	1,678	5,212	+210.6%	$9.2K	2025-Q1
CITADEL ADVISORS LLC	ADD	58,117	101,552	+74.7%	$231.5K	2024-Q4
UBS Group AG	DOUBLED	12,643	41,147	+225.5%	$93.8K	2024-Q4
WELLS FARGO & COMPANY/MN	ADD	17,512	26,915	+53.7%	$61.4K	2024-Q4
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	NEW	—	167,297	—	$341.3K	2024-Q3
MORGAN STANLEY	DOUBLED	77,223	160,767	+108.2%	$328.0K	2024-Q3

1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Apr 11, 2026	Peery Kimberly R.	Chief Financial Officer	A	40,000	$0.00	$0.00

7 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 2 mixed, 3 neutral. Avg impact: 4.9/10.

BEARISH 8-K 6/10

Stereotaxis reported Q1 2026 revenue of $6.3M, down 16% YoY from $7.5M, and a GAAP net loss per shar

May 12, 2026

MIXED PRESS-RELEASE 6/10

Stereotaxis reported Q1 2026 revenue of $6.3M (down 16% YoY from $7.5M) and EPS of -$0.06, missing t

May 12, 2026

NEUTRAL PRESS-RELEASE 3/10

Stereotaxis announced a future earnings release date for Q1 2026, with no financial results or guida

Apr 21, 2026

MIXED 8-K 6/10

Stereotaxis is acquiring French robotics firm Robocath for $20 million upfront plus up to $25 millio

Apr 15, 2026

NEUTRAL DEFA14A 3/10

Stereotaxis, Inc. filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting,

Apr 3, 2026

NEUTRAL EFFECT 4/10

Stereotaxis, Inc. has filed an EFFECT notice indicating that its shelf registration statement on For

Mar 23, 2026

BEARISH S-3 6/10

Stereotaxis filed an S-3 shelf registration to potentially raise up to $150 million, combining a new

Mar 13, 2026

BULLISH 7/10

Stereotaxis (STXS) announced a definitive agreement to acquire Robocath, a French innovator in robot

Apr 15, 2026

BULLISH 7/10

Stereotaxis announced FDA 510(k) clearance for its Synchrony™ system, a digital platform designed to

Apr 6, 2026

Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$4.13 mean target +123.0% upside Strong Buy (1.50)

$3.50 Low $5.00 High

Metric	Value
Current Price	$1.85
Target Low	$3.50
Target Mean	$4.13
Target Median	$4.00
Target High	$5.00
# Analysts	4
Recommendation	Strong Buy (1.50)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-0.05	$-0.06	$-0.03	6.7%	+11.1%	1↑ 0↓	$0.0B	-5.1%	3
Next Q 2026-09-30	$-0.05	$-0.06	$-0.04	33.3%	-16.7%	0↑ 1↓	$0.0B	47.0%	3
Current FY 2026-12-31	$-0.19	$-0.23	$-0.17	24.0%	-2.7%	0↑ 1↓	$0.0B	21.7%	3
Next FY 2027-12-31	$-0.13	$-0.18	$-0.07	33.3%	-3.4%	0↑ 1↓	$0.1B	35.2%	3

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.047
7d ago	$-0.052	+0.006
30d ago	$-0.052	+0.006
60d ago	$-0.052	+0.006
90d ago	$-0.057	+0.010

2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
May 13, 2026	Piper Sandler	REITERATE	Overweight	Overweight
Dec 16, 2025	Citizens	INITIATE	—	Market Outperform

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	2	7	1	90%
May 1, 2026	2	8	1	91%
Apr 1, 2026	2	8	1	91%
Mar 1, 2026	2	8	1	91%
Feb 1, 2026	2	8	1	91%
Jan 1, 2026	2	8	1	91%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 12, 2026

earnings

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2pZ5p0tV9VmbHdG7AP9_TugdOsxT4AN4o

May 12, 2026

earnings_calendar

STXS Q1 2026 Earnings After Market Close — 2026-05-12

Apr 22, 2026

other

Stereotaxis Announces First MAGiC Procedures in the United States

ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for mini

Apr 21, 2026

earnings

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=aFHeGYVL4IVkW6_hiMBCSA96YnptKBHiBTale0adty4CUys

Apr 15, 2026

m_and_a

Stereotaxis Announces Definitive Agreement to Acquire Robocath

ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=HPlOpY4plg9UR

Apr 6, 2026

fda

Stereotaxis Announces FDA Clearance and Launch of Synchrony System

ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for mini

Mar 9, 2026

earnings

Stereotaxis Reports 2025 Full Year Financial Results

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Fkdcv1-diVOdexz6AdOY6Bc2TMWNKim

Mar 9, 2026

earnings_calendar

STXS Q4 2025 Earnings After Market Close — 2026-03-09